The Journal of Thoracic and Cardiovascular Surgery
Volume 136, Issue 1 , Pages 52-57, July 2008

Deleterious outcome of No-React–treated stentless valved conduits after aortic root replacement: Why were Warnings ignored?

Department of Cardiovascular Surgery, University Hospital, Berne, Switzerland

Received 22 August 2007; accepted 11 September 2007. published online 27 May 2008.

Objective

The implantation of a composite graft is the treatment of choice for patients with aortic root disease if the valve cannot be preserved and the patient is not a suitable candidate for a Ross procedure. Several years ago, the Shelhigh NR-2000C (Shelhigh, Inc, Millburn, NJ) was introduced in Europe. Being a totally biologic conduit and considering the lack of homografts, the graft seemed an ideal conduit for patients with destructive endocarditis, as well as for older patients who were not suitable candidates for oral anticoagulation.

Methods

From 2001 until 2006, the Shelhigh NR-2000C stentless valved conduit was implanted in 115 patients for various aortic root pathologies. The conduit consists of a bovine pericardial straight graft with an incorporated porcine stentless valve. Aortic root repair was performed during standard cardiopulmonary bypass and mild hypothermia in the majority of patients. Deep hypothermic circulatory arrest combined with selective antegrade cerebral perfusion was used when the repair extended into the arch.

Results

Seven patients with uncomplicated early outcome presented with unexpected sudden disastrous findings at the level of the aortic root, although 1-year follow-up computed tomographic scans were normal. Four of these patients underwent emergency operations because of desintegration of the graft, along with rupture of the aortic root. Retrospectively, the main findings were persistent fever or subfebrility over months and a halo-like enhancement on computed tomographic scans. Extensive microbiologic examinations were performed without finding a causative organism.

Conclusion

The use of the Shelhigh aortic stentless conduit can no longer be advocated, and meticulous follow-up of patients in whom this device has been implanted has to be recommended.

Abbreviations and Acronyms: CT, computed tomography, FDA, US Food and Drug Administration

CTSNet classification: 4, 26, 35

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The Shelhigh NR-2000C is a totally biologic stentless conduit designed for the treatment of various aortic root pathologies. After implanting 115 conduits, 7 patients presented with disastrous findings, including aortic root rupture. Meticulous follow-up of those patients who already underwent implantation of this device has to be recommended.

 Thierry Carrel reports terminating a previous relationship with Shelhigh.

PII: S0022-5223(07)01692-3

doi:10.1016/j.jtcvs.2007.09.047

The Journal of Thoracic and Cardiovascular Surgery
Volume 136, Issue 1 , Pages 52-57, July 2008